IL165498A0 - Oncolyic viruses as phenotyping agents for neoplasms - Google Patents

Oncolyic viruses as phenotyping agents for neoplasms

Info

Publication number: IL165498A0
Authority: IL; Israel
Prior art keywords: oncolyic; phenotyping; neoplasms; viruses; agents
Prior art date: 2002-06-28

Application number

IL16549804A

Other languages

English (en)

Original Assignee

Oncolytics Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-28

Filing date

2004-12-01

Publication date

2006-01-15

2004-12-01 Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc

2006-01-15 Publication of IL165498A0 publication Critical patent/IL165498A0/xx

Classifications

- G01N33/575—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G01N33/57575—
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Hospice & Palliative Care (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)

IL16549804A 2002-06-28 2004-12-01 Oncolyic viruses as phenotyping agents for neoplasms IL165498A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39203102P	2002-06-28	2002-06-28
US44318803P	2003-01-29	2003-01-29
PCT/CA2003/000951 WO2004003562A2 (en)	2002-06-28	2003-06-25	Oncolytic viruses as phenotyping agents for neoplasms

Publications (1)

Publication Number	Publication Date
IL165498A0 true IL165498A0 (en)	2006-01-15

Family

ID=30003222

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16549804A IL165498A0 (en)	2002-06-28	2004-12-01	Oncolyic viruses as phenotyping agents for neoplasms
IL220139A IL220139A (en)	2002-06-28	2012-06-04	Oncolytic viruses as phenotying agents for neoplasms

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL220139A IL220139A (en)	2002-06-28	2012-06-04	Oncolytic viruses as phenotying agents for neoplasms

Country Status (19)

Country	Link
US (3)	US7306902B2 (xx)
EP (2)	EP1520175B1 (xx)
JP (1)	JP2005531306A (xx)
CN (1)	CN1666105B (xx)
AR (1)	AR039768A1 (xx)
AT (2)	ATE377754T1 (xx)
AU (2)	AU2003245760B2 (xx)
BR (1)	BR0311983A (xx)
CA (1)	CA2487824C (xx)
DE (1)	DE60317331T2 (xx)
DK (2)	DK1520175T3 (xx)
ES (2)	ES2385845T3 (xx)
IL (2)	IL165498A0 (xx)
MX (1)	MXPA04012414A (xx)
NZ (1)	NZ537116A (xx)
PT (1)	PT1890151E (xx)
SI (1)	SI1890151T1 (xx)
TW (3)	TWI334444B (xx)
WO (1)	WO2004003562A2 (xx)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPQ425699A0 (en)	1999-11-25	1999-12-23	University Of Newcastle Research Associates Limited, The	A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en) *	2000-05-03	2013-07-23	Oncolytics Biotech Inc.	Virus clearance of neoplastic cells from mixed cellular compositions
US7306902B2 (en) *	2002-06-28	2007-12-11	Oncolyties Biotech Inc.	Oncolytic viruses as phenotyping agents for neoplasms
US20040115170A1 (en) *	2001-11-30	2004-06-17	Brown Earl Garnet	Oncolytic virus
EP1523333A4 (en)	2002-07-24	2007-01-24	Univ Arizona	USE OF VACCINIA VIRUS WITH DELETION OF E3L GENE AS VACCINE VECTOR
AU2002953436A0 (en)	2002-12-18	2003-01-09	The University Of Newcastle Research Associates Limited	A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005007824A2 (en) *	2003-07-08	2005-01-27	Arizona Board Of Regents	Mutants of vaccinia virus as oncolytic agents
WO2005111200A1 (en) *	2004-05-17	2005-11-24	Universite De Montreal	Novel strains of reoviruses and methods of uses thereof
US10668119B2 (en)	2005-08-01	2020-06-02	Virocure, Inc.	Attenuated reovirus
EP1917351A4 (en)	2005-08-01	2009-12-16	Univ Technologies Int	ATTENUATED REOVIRUS
ATE516370T1 (de) *	2005-12-22	2011-07-15	Sloan Kettering Inst Cancer	Verfahren zur erfassung von krebszellen unter verwendung eines virus
DK1984007T3 (en) *	2006-02-13	2015-12-07	Oncolytics Biotech Inc	Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy
US10369171B2 (en)	2007-03-13	2019-08-06	Virocure, Inc.	Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) *	2007-05-21	2008-11-27	Board Of Regents, University Of Texas System	Methods and compositions for treatment of cancer using oncolytic rsv activity
CN102124335B (zh) *	2008-05-22	2014-07-30	第一药品株式会社	基于肿瘤抑制因子的过度增生细胞对溶瘤病毒疗法的敏感性
MX339014B (es) *	2008-05-27	2016-05-09	Oncolytics Biotech Inc	Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
CN102065873A (zh) *	2008-05-27	2011-05-18	昂科利蒂克斯生物科技公司	在溶瘤呼肠孤病毒治疗中消除促炎细胞因子的产生
US8481297B2 (en) *	2009-01-08	2013-07-09	Yale University	Compositions and methods of use of an oncolytic vesicular stomatitis virus
ES2385251B1 (es)	2009-05-06	2013-05-06	Fundació Privada Institut D'investigació Biomèdica De Bellvitge	Adenovirus oncolíticos para el tratamiento del cáncer.
EP2670426B1 (en)	2011-01-31	2017-05-10	The General Hospital Corporation	Multimodal trail molecules and uses in cellular therapies
US8859256B2 (en)	2011-10-05	2014-10-14	Genelux Corporation	Method for detecting replication or colonization of a biological therapeutic
US20140087362A1 (en)	2012-03-16	2014-03-27	Aladar A. Szalay	Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en)	2012-04-20	2013-10-24	Genelux Corporation	Imaging methods for oncolytic virus therapy
EP3473708B1 (en)	2012-07-24	2021-01-27	The General Hospital Corporation	Oncolytic virus therapy for resistant tumors
US9605074B2 (en)	2012-08-30	2017-03-28	The General Hospital Corporation	Multifunctional nanobodies for treating cancer
WO2014055960A1 (en)	2012-10-05	2014-04-10	Genelux Corporation	Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
US20160303174A1 (en) *	2013-12-11	2016-10-20	The General Hospital Corporation	Stem cell delivered oncolytic herpes simplex virus and methods for treating brain tumors
WO2015103438A2 (en)	2014-01-02	2015-07-09	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity
CA2964317C (en)	2014-10-14	2021-10-05	Halozyme, Inc.	Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
EP3261669B1 (en)	2015-02-25	2022-08-03	Memorial Sloan Kettering Cancer Center	Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CN116173193A (zh)	2015-04-17	2023-05-30	纪念斯隆凯特琳癌症中心	Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
AU2017222687B2 (en)	2016-02-25	2022-02-24	Memorial Sloan Kettering Cancer Center	Recombinant MVA or MVADELE3L expressing human Flt3L and use thereof as immuno-therapeutic agents against solid tumors
BR112018016949A2 (pt)	2016-02-25	2019-01-08	Memorial Sloan Kettering Cancer Center	vírus vaccinia atenuado competente em relação à replicação como deleção de timidina quinase com ou sem a expressão de flt3l ou gm-csf humano para imunoterapia de câncer
JP7527758B2 (ja)	2016-04-15	2024-08-05	アルパインイミューンサイエンシズインコーポレイテッド	Ｃｄ８０バリアント免疫調節タンパク質およびその使用
KR102824067B1 (ko)	2016-04-15	2025-06-23	알파인 이뮨 사이언시즈, 인코포레이티드	Icos 리간드 변이체 면역조절 단백질 및 그의 용도
US10842835B2 (en)	2016-05-25	2020-11-24	Arizona Board Of Regents On Behalf Of Arizona State University	Oncolytic vaccinia virus mutants and using same for cancer treatment
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
WO2018022946A1 (en)	2016-07-28	2018-02-01	Alpine Immune Sciences, Inc.	Cd155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en)	2016-07-28	2023-12-05	Alpine Immune Sciences, Inc.	CD112 variant immunomodulatory proteins and uses thereof
EP4019029A1 (en) *	2016-09-27	2022-06-29	Sator Therapeutics LLC	Optimized oncolytic viruses and uses thereof
WO2018075978A1 (en)	2016-10-20	2018-04-26	Alpine Immune Sciences, Inc.	Secretable variant immunomodulatory proteins and engineered cell therapy
JP2020507349A (ja)	2017-02-09	2020-03-12	インダプタセラピューティクスインコーポレイテッド	操作されたナチュラルキラー（ｎｋ）細胞ならびにその組成物および方法
CA3053804C (en)	2017-03-16	2025-09-23	Alpine Immune Sciences, Inc.	Immunomodulatory Proteins of PD-L1 Variants and Associated Uses
MX2019010887A (es)	2017-03-16	2019-10-15	Alpine Immune Sciences Inc	Proteinas inmunomoduladoras de cb80 variante y usos de estas.
US11732022B2 (en)	2017-03-16	2023-08-22	Alpine Immune Sciences, Inc.	PD-L2 variant immunomodulatory proteins and uses thereof
WO2018209315A1 (en)	2017-05-12	2018-11-15	Memorial Sloan Kettering Cancer Center	Vaccinia virus mutants useful for cancer immunotherapy
TWI899046B (zh)	2017-10-18	2025-10-01	美商艾爾潘免疫科學有限公司	變異型icos 配位體免疫調節蛋白及相關組合物及方法
SG11202006148UA (en)	2018-01-03	2020-07-29	Alpine Immune Sciences Inc	Multi-domain immunomodulatory proteins and methods of use thereof
US11505782B2 (en)	2018-06-04	2022-11-22	Calidi Biotherapeutics, Inc.	Cell-based vehicles for potentiation of viral therapy
ES2966045T3 (es)	2018-06-04	2024-04-18	Calidi Biotherapeutics Inc	Vehículos basados en células para la potenciación de la terapia viral
WO2019241758A1 (en)	2018-06-15	2019-12-19	Alpine Immune Sciences, Inc.	Pd-1 variant immunomodulatory proteins and uses thereof
WO2020047161A2 (en)	2018-08-28	2020-03-05	Actym Therapeutics, Inc.	Engineered immunostimulatory bacterial strains and uses thereof
SG11202102439WA (en)	2018-09-15	2021-04-29	Memorial Sloan Kettering Cancer Center	Recombinant poxviruses for cancer immunotherapy
CN113271955A (zh)	2018-11-06	2021-08-17	卡利迪生物治疗有限公司	用于细胞介导的溶瘤病毒疗法的增强的系统
JP7541516B2 (ja)	2018-11-21	2024-08-28	インダプタセラピューティクスインコーポレイテッド	ナチュラルキラー（ｎｋ）細胞サブセットの増大のための方法ならびに関連する組成物および方法
KR20210135987A (ko)	2018-11-30	2021-11-16	알파인 이뮨 사이언시즈, 인코포레이티드	Cd86 변이체 면역조절 단백질 및 그의 용도
CA3176660A1 (en)	2019-02-27	2020-09-03	Actym Therapeutics, Inc.	Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en)	2019-02-27	2024-07-02	Actym Therapeutics, Inc.	Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
AU2021258194A1 (en)	2020-04-22	2022-11-24	Indapta Therapeutics, Inc.	Natural killer (NK) cell compositions and methods for generating same
TW202241479A (zh)	2020-12-30	2022-11-01	美商安迅生物製藥公司	遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747469A (en) *	1991-03-06	1998-05-05	Board Of Regents, The University Of Texas System	Methods and compositions comprising DNA damaging agents and p53
US5670330A (en) *	1992-09-29	1997-09-23	Mcgill University	Anti-tumor agent assay using PKR
PT931830E (pt)	1993-02-16	2001-08-30	Onyx Pharma Inc	Virus citopaticos para terapia e profilaxia de neoplasia
US5801029A (en) *	1993-02-16	1998-09-01	Onyx Pharmaceuticals, Inc.	Cytopathic viruses for therapy and prophylaxis of neoplasia
DE69435118D1 (de)	1993-04-30	2008-08-28	Wellstat Biologics Corp	Gereinigte Zusammensetzungen von Newcastle-Krankheitvirus
CA2178902A1 (en) *	1993-12-14	1995-06-22	Drew Pardoll	Controlled release of pharmaceutically active substances for immunotherapy
WO1995032300A1 (en) *	1994-05-23	1995-11-30	University Of Medicine & Dentistry Of New Jersey	Selective biological destruction of tumor cells
US5585096A (en) *	1994-06-23	1996-12-17	Georgetown University	Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5840502A (en) *	1994-08-31	1998-11-24	Activated Cell Therapy, Inc.	Methods for enriching specific cell-types by density gradient centrifugation
US6777177B1 (en) *	1997-10-10	2004-08-17	Vanderbilt University	Mammalian genes involved in viral infection and tumor suppression
CA2508238C (en)	1997-08-13	2008-01-15	Oncolytics Biotech Inc.	Reovirus for the treatment of neoplasia
US6136307A (en) *	1997-08-13	2000-10-24	Oncolytics Biotech Inc.	Reovirus for the treatment of cellular proliferative disorders
US6110461A (en)	1997-08-13	2000-08-29	Oncolytics Biotech Inc.	Reovirus for the treatment of neoplasia
AU9603898A (en) *	1997-10-09	1999-05-03	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US7780962B2 (en) *	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
US6475481B2 (en) *	1997-11-18	2002-11-05	Canji Inc	Purging of stem cell products
CA2323067A1 (en)	1998-03-12	1999-09-16	The Trustees Of The University Of Pennsylvania	Producer cells for replication selective viruses in the treatment of malignancy
WO2000012103A1 (en) *	1998-08-31	2000-03-09	Ambrus Julian L	Method for removal of hiv and other viruses from blood
HUP0302278A3 (en)	1999-04-15	2011-01-28	Pro Virus	Treatment of neoplasms with viruses
DE19934788B4 (de) *	1999-07-27	2004-05-27	T-Mobile Deutschland Gmbh	Verfahren zur automatischen Anpassung von Daten an die Fähigkeiten einer Nutzer-Software
EP1716858B9 (en)	1999-09-17	2009-08-12	Wellstat Biologics Corporation	Oncolytic virus
BR0015491A (pt) *	1999-11-12	2002-10-15	Oncolytics Biotech Inc	Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
AUPQ425699A0 (en)	1999-11-25	1999-12-23	University Of Newcastle Research Associates Limited, The	A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AR028040A1 (es)	2000-05-03	2003-04-23	Oncolytics Biotech Inc	Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
US7306902B2 (en) *	2002-06-28	2007-12-11	Oncolyties Biotech Inc.	Oncolytic viruses as phenotyping agents for neoplasms
AR028039A1 (es) *	2000-05-03	2003-04-23	Oncolytics Biotech Inc	Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
HK1052950B (en) *	2000-06-26	2005-06-24	Wellstat Biologics Corporation	Purging of cells using viruses
WO2002004596A2 (en)	2000-07-07	2002-01-17	President And Fellows Of Harvard College	Diagnosing and treating cancer cells using mutant viruses
MXPA03004029A (es)	2000-11-09	2004-02-12	Oncolytics Biotech Inc	Metodos para tratamiento de trastornos proliferativos celulares.
US20030138405A1 (en) *	2001-04-17	2003-07-24	Juan Fueyo	Conditionally replicative adenovirus to target the Rb and Rb-related pathways

2003
- 2003-06-24 US US10/602,024 patent/US7306902B2/en not_active Expired - Lifetime
- 2003-06-25 DK DK03737795T patent/DK1520175T3/da active
- 2003-06-25 NZ NZ537116A patent/NZ537116A/en unknown
- 2003-06-25 WO PCT/CA2003/000951 patent/WO2004003562A2/en not_active Ceased
- 2003-06-25 EP EP03737795A patent/EP1520175B1/en not_active Expired - Lifetime
- 2003-06-25 JP JP2004516379A patent/JP2005531306A/ja active Pending
- 2003-06-25 ES ES07021569T patent/ES2385845T3/es not_active Expired - Lifetime
- 2003-06-25 DE DE60317331T patent/DE60317331T2/de not_active Expired - Lifetime
- 2003-06-25 SI SI200332164T patent/SI1890151T1/sl unknown
- 2003-06-25 CN CN03815353.XA patent/CN1666105B/zh not_active Expired - Lifetime
- 2003-06-25 MX MXPA04012414A patent/MXPA04012414A/es active IP Right Grant
- 2003-06-25 AT AT03737795T patent/ATE377754T1/de not_active IP Right Cessation
- 2003-06-25 ES ES03737795T patent/ES2292981T3/es not_active Expired - Lifetime
- 2003-06-25 BR BR0311983-1A patent/BR0311983A/pt not_active IP Right Cessation
- 2003-06-25 DK DK07021569.4T patent/DK1890151T3/da active
- 2003-06-25 CA CA2487824A patent/CA2487824C/en not_active Expired - Lifetime
- 2003-06-25 EP EP07021569A patent/EP1890151B1/en not_active Expired - Lifetime
- 2003-06-25 PT PT07021569T patent/PT1890151E/pt unknown
- 2003-06-25 AT AT07021569T patent/ATE555388T1/de active
- 2003-06-25 AU AU2003245760A patent/AU2003245760B2/en not_active Expired
- 2003-06-26 TW TW098135545A patent/TWI334444B/zh not_active IP Right Cessation
- 2003-06-26 AR ARP030102317A patent/AR039768A1/es unknown
- 2003-06-26 TW TW092117377A patent/TWI327167B/zh not_active IP Right Cessation
- 2003-06-26 TW TW098118162A patent/TWI402345B/zh not_active IP Right Cessation
2004
- 2004-12-01 IL IL16549804A patent/IL165498A0/xx active IP Right Grant
2007
- 2007-05-30 US US11/807,771 patent/US20080014577A1/en not_active Abandoned
2008
- 2008-08-28 AU AU2008207579A patent/AU2008207579B2/en not_active Expired
2010
- 2010-01-05 US US12/652,289 patent/US8222036B2/en not_active Expired - Fee Related
2012
- 2012-06-04 IL IL220139A patent/IL220139A/en active IP Right Grant

Also Published As

Publication number	Publication date
JP2005531306A (ja)	2005-10-20
AU2008207579B2 (en)	2011-10-20
DK1890151T3 (da)	2012-06-18
PT1890151E (pt)	2012-05-25
DE60317331D1 (de)	2007-12-20
WO2004003562A3 (en)	2004-05-06
AU2003245760A1 (en)	2004-01-19
HK1112509A1 (en)	2008-09-05
ATE555388T1 (de)	2012-05-15
EP1520175B1 (en)	2007-11-07
AR039768A1 (es)	2005-03-09
US8222036B2 (en)	2012-07-17
US20080014577A1 (en)	2008-01-17
TW200940709A (en)	2009-10-01
US20040029112A1 (en)	2004-02-12
TW201005097A (en)	2010-02-01
EP1890151B1 (en)	2012-04-25
BR0311983A (pt)	2005-04-26
TWI327167B (en)	2010-07-11
ES2385845T3 (es)	2012-08-01
SI1890151T1 (sl)	2012-08-31
CN1666105A (zh)	2005-09-07
DK1520175T3 (da)	2008-02-11
ES2292981T3 (es)	2008-03-16
IL220139A0 (en)	2012-07-31
DE60317331T2 (de)	2008-08-21
MXPA04012414A (es)	2005-04-19
TWI402345B (zh)	2013-07-21
NZ537116A (en)	2008-04-30
US7306902B2 (en)	2007-12-11
US20100105122A1 (en)	2010-04-29
EP1890151A1 (en)	2008-02-20
AU2003245760B2 (en)	2008-07-03
TWI334444B (en)	2010-12-11
ATE377754T1 (de)	2007-11-15
EP1520175A2 (en)	2005-04-06
CA2487824C (en)	2013-08-20
AU2008207579A1 (en)	2008-09-18
WO2004003562A2 (en)	2004-01-08
CA2487824A1 (en)	2004-01-08
TW200401032A (en)	2004-01-16
CN1666105B (zh)	2015-11-25
IL220139A (en)	2013-03-24
HK1069877A1 (en)	2005-06-03

Publication	Publication Date	Title
IL165498A0 (en)	2006-01-15	Oncolyic viruses as phenotyping agents for neoplasms
TWI341314B (en)	2011-05-01	New compounds
IL177933A0 (en)	2006-12-31	New compounds
IL166650A0 (en)	2006-01-15	New compounds
AU2003264018A8 (en)	2004-02-25	New compounds
IL163894A0 (en)	2005-12-18	New compounds
EP1558585A4 (en)	2008-07-02	NEUROLOGICALLY ACTIVE COMPOUNDS
GB0209022D0 (en)	2002-05-29	Compounds
GB0200283D0 (en)	2002-02-20	Compounds
HU0203976D0 (en)	2003-01-28	New compounds
AU2003216859A8 (en)	2003-10-08	Amidoacetonitrile compounds
GB0210762D0 (en)	2002-06-19	Compounds
GB0211418D0 (en)	2002-06-26	Compounds
GB0207323D0 (en)	2002-05-08	Compounds
GB0203778D0 (en)	2002-04-03	Compounds
ZA200409895B (en)	2006-05-31	Oncolytic viruses as phenotyping agents for neoplasms
GB0209244D0 (en)	2002-06-05	Compounds
GB0203811D0 (en)	2002-04-03	Compounds
EP1463794A4 (en)	2005-11-16	IMIDAZOLINE QUATERNARY COMPOUNDS
GB0206981D0 (en)	2002-05-08	Compounds
GB0219619D0 (en)	2002-10-02	anti-neoplastic viruses
GB0203807D0 (en)	2002-04-03	Compounds
GB0203438D0 (en)	2002-04-03	Compounds
GB0203435D0 (en)	2002-04-03	Compounds
GB0203191D0 (en)	2002-03-27	Compounds

Legal Events

Date	Code	Title
2012-12-31	FF	Patent granted
2013-02-28	KB	Patent renewed
2013-06-27	KB	Patent renewed
2017-05-29	KB	Patent renewed
2021-06-30	KB	Patent renewed